-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
Latest News
-
Vico’s Trial Adjusts With Twice-Yearly Dosing, And The U.S. Is Next
⏱️ 6 min read | Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested just twice a year, and the FDA has cleared the way for US trials to begin later this year.
-
Minocycline: the end of the road?
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
-
TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Alnylam Pharmaceuticals
Expected:
2026
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Novartis/PTC Therapeutics
Expected:
Not disclosed
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Skyhawk Therapeutics
Expected:
Not disclosed